person · Reporting owner

Gutierrez-Ramos Jose-Carlos

Disclosed activity across 5 companies

Tapewire entity: 14341
SEC CIK: 0001667657

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BICYCLE THERAPEUTICS PLCBCYC · Entity 5993	Director	January 02, 2026	January 07, 2026
DANAHER CORP /DE/DHR · Entity 2871	SVP, Chief Science Officer	August 04, 2026	August 06, 2026
Evelo Biosciences, Inc.EVLO · Entity 108468	Director	June 08, 2023	June 12, 2023
SYNLOGIC, INC.SYBX · Entity 7801	Director · See Remarks	March 14, 2018	March 16, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BICYCLE THERAPEUTICS PLC

Report date January 02, 2026 · Filed January 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	32,500	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 9,500 · Balance 32,500 F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2: Each RSU represents a contingent right to receive one ordinary share.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02	Direct	19,000	Reported balance After 2026-01-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-02 · Grant · Acquired 19,000 · Balance 19,000 F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

F2: Each RSU represents a contingent right to receive one ordinary share.

F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

DANAHER CORP /DE/

Report date August 04, 2026 · Filed August 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	32,495	Reported balance After 2026-08-04 transaction · row 1 1 source row Row 1 · 2026-08-04 · Grant · Acquired 13,477 · Balance 32,495 F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated in connection with the Issuer's Long-Term Growth Program, as previously reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One hundred percent of the RSUs vest on the 12-month anniversary of the grant date, which is August 4, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated in connection with the Issuer's Long-Term Growth Program, as previously reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One hundred percent of the RSUs vest on the 12-month anniversary of the grant date, which is August 4, 2026.

Evelo Biosciences, Inc.

Report date June 08, 2023 · Filed June 12, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.11 · Expires 2033-06-08	Direct	20,000	Reported balance After 2023-06-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-08 · Grant · Acquired 20,000 · Balance 20,000 F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant.

SYNLOGIC, INC.

Report date March 14, 2018 · Filed March 16, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2028-03-14	Direct	120,540	Reported balance After 2018-03-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-14 · Grant · Acquired 120,540 · Balance 120,540 F1: The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest and become exercisable in substantially equal monthly installments beginning on April 14, 2018 and continuing until March 14, 2022, subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MOMENTA PHARMACEUTICALS INC

Report date October 01, 2020 · Filed October 01, 2020

Section 16 reporting ended · disclosed 2020-10-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2026-03-09	Direct	Reported balance After 2020-10-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-10-01 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.20 · Expires 2027-06-20	Direct	Reported balance After 2020-10-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-10-01 · Disposition to issuer · Disposed 11,207 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.30 · Expires 2028-06-20	Direct	Reported balance After 2020-10-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-01 · Disposition to issuer · Disposed 8,855 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2029-06-19	Direct	Reported balance After 2020-10-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.09 · Expires 2030-06-23	Direct	Reported balance After 2020-10-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 04, 2026 Filed Aug 6, 2026 21:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	13,477	$0.00	$0.00	Disclosure SEC source: 0000313616-26-000183 · wk-form4_1786050057.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,495 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated in connection with the Issuer's Long-Term Growth Program, as previously reported in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 3, 2026. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One hundred percent of the RSUs vest on the 12-month anniversary of the grant date, which is August 4, 2026. Read SEC document
March 01, 2026 Filed Mar 4, 2026 00:52 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock option (right to buy) · Derivative	17,964	$0.00 Strike: $210.64	$0.00	Disclosure SEC source: 0000313616-26-000094 · wk-form4_1772585524.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,964 Underlying: Common Stock · 17,964 shares Expires 2036-03-01 F2 · derivative.exercise_date: Fifty percent of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is March 1, 2026. Read SEC document
March 01, 2026 Filed Mar 4, 2026 00:52 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	284	$210.64	$59,821.76	Disclosure SEC source: 0000313616-26-000094 · wk-form4_1772585524.xml · nonDerivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,018 Read SEC document
March 01, 2026 Filed Mar 4, 2026 00:52 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	6,647	$0.00	$0.00	Disclosure SEC source: 0000313616-26-000094 · wk-form4_1772585524.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,302 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. Twenty-five percent of the RSUs vest on each of the first four anniversaries of the grant date, which is March 1, 2026. Read SEC document
February 24, 2026 Filed Feb 25, 2026 22:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	344	$209.19	$71,961.36	Disclosure SEC source: 0000313616-26-000073 · wk-form4_1772056903.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,655 Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	1,695	$0.00	$0.00	Disclosure SEC source: 0000313616-26-000054 · wk-form4_1770415274.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,999 F1 · shares: On February 24, 2023, the Compensation Committee of the Company's Board of Directors awarded the reporting person performance stock units under the Danaher Corporation 2007 Omnibus Incentive Plan. This Form 4 is being filed in connection with the determination by the Compensation Committee that the performance criteria of the award have been achieved. The award remains subject to a holding period that continues through December 31, 2027. Read SEC document
February 02, 2026 Filed Feb 4, 2026 22:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	275	$218.89 Strike: $0.00	$60,194.75	Disclosure SEC source: 0000313616-26-000040 · wk-form4_1770242481.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,447.296 Underlying: Common Stock · 275 shares Expires not disclosed F2 · security: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F3 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F4 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F4 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
February 02, 2026 Filed Feb 4, 2026 22:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	852	$223.42	$190,353.84	Disclosure SEC source: 0000313616-26-000040 · wk-form4_1770242481.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,304 F1 · shares: This transaction relates to the withholding of certain shares for tax purposes in connection with the distribution of performance-based restricted stock units. Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	19,000	$0.00 Strike: $7.08	$0.00	Disclosure SEC source: 0001667657-26-000002 · form4-01062026_080104.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 19,000 shares Expires 2036-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. Read SEC document
January 02, 2026 Filed Jan 7, 2026 01:00 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	9,500	$0.00	$0.00	Disclosure SEC source: 0001667657-26-000002 · form4-01062026_080104.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 F1 · shares: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
March 01, 2025 Filed Mar 4, 2025 22:00 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock option (right to buy) · Derivative	24,067	$0.00 Strike: $207.76	$0.00	Disclosure SEC source: 0000313616-25-000066 · wk-form4_1741125609.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,067 Underlying: Common Stock · 24,067 shares Expires 2035-03-01 F1 · derivative.exercise_date: One half of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is March 1, 2025. Read SEC document
March 01, 2025 Filed Mar 4, 2025 22:00 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	216	$207.76	$44,876.16	Disclosure SEC source: 0000313616-25-000066 · wk-form4_1741125609.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,156 Read SEC document
February 24, 2025 Filed Feb 25, 2025 22:02 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	586	$211.14	$123,728.04	Disclosure SEC source: 0000313616-25-000056 · wk-form4_1740520932.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,372 Read SEC document
February 01, 2025 Filed Feb 4, 2025 22:34 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	241	$222.74 Strike: $0.00	$53,680.34	Disclosure SEC source: 0000313616-25-000026 · wk-form4_1738708480.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,172.296 Underlying: Common Stock · 241 shares Expires not disclosed F1 · security: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
January 02, 2025 Filed Jan 7, 2025 00:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	12,500	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001415889-25-000917 · form4-01062025_070104.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. Read SEC document
January 02, 2025 Filed Jan 7, 2025 00:30 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	6,250	$0.00	$0.00	Disclosure SEC source: 0001415889-25-000917 · form4-01062025_070104.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2025, June 15, 2025, September 15, 2025 and December 15, 2025. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:05 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock option (right to buy) · Derivative	6,979	$0.00 Strike: $255.87	$0.00	Disclosure SEC source: 0000313616-24-000100 · wk-form4_1709676316.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,979 Underlying: Common Stock · 6,979 shares Expires 2034-03-01 F3 · derivative.exercise_date: One fourth of the options granted become exercisable on each of the first four anniversaries of the grant date, which is March 1, 2024. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:05 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock option (right to buy) · Derivative	16,285	$0.00 Strike: $255.87	$0.00	Disclosure SEC source: 0000313616-24-000100 · wk-form4_1709676316.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,285 Underlying: Common Stock · 16,285 shares Expires 2034-03-01 F2 · derivative.exercise_date: One half of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is March 1, 2024. Read SEC document
March 01, 2024 Filed Mar 5, 2024 22:05 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	2,932	$0.00	$0.00	Disclosure SEC source: 0000313616-24-000100 · wk-form4_1709676316.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,958 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One fourth of the RSUs vest on each of the first four anniversaries of the grant date, which is March 1, 2024. Read SEC document
February 26, 2024 Filed Feb 27, 2024 22:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	866	$253.84	$219,825.44	Disclosure SEC source: 0000313616-24-000078 · wk-form4_1709071295.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,026 Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:03 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	3,155	$0.00	$0.00	Disclosure SEC source: 0000313616-24-000067 · wk-form4_1708725757.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,892 F1 · shares: On February 24, 2021, the Compensation Committee of the Company's Board of Directors awarded the reporting person performance stock units under the Danaher Corporation 2007 Omnibus Incentive Plan. This Form 4 is being filed in connection with the determination by the Compensation Committee that the performance criteria of the award have been achieved. The award remains subject to a holding period that continues through December 31, 2025. Read SEC document
February 01, 2024 Filed Feb 2, 2024 22:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	216	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000313616-24-000035 · wk-form4_1706911258.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 931.296 Underlying: Common Stock · 216 shares Expires not disclosed F1 · security: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F1 · derivative.underlying_shares: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. F1 · balance_after: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. Read SEC document
January 02, 2024 Filed Jan 4, 2024 23:33 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $18.08	$0.00	Disclosure SEC source: 0001209191-24-000885 · doc4.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2034-01-02 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. Read SEC document
January 02, 2024 Filed Jan 4, 2024 23:33 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	6,000	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000885 · doc4.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,750 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
August 21, 2023 Filed Aug 22, 2023 21:00 UTC	DANAHER CORP /DE/ DHR · Entity 2871	SaleCommon Stock	590	$250.54	$147,818.60	Disclosure SEC source: 0000313616-23-000246 · wk-form4_1692738028.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,939 Read SEC document
June 08, 2023 Filed Jun 12, 2023 16:07 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.11	$0.00	Disclosure SEC source: 0001694665-23-000088 · wk-form4_1686600439.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The option vests on the earlier of June 8, 2024, and the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of the grant. Read SEC document
May 01, 2023 Filed May 2, 2023 21:01 UTC	DANAHER CORP /DE/ DHR · Entity 2871	SaleCommon Stock	500	$242.19	$121,096.40	Disclosure SEC source: 0000313616-23-000167 · wf-form4_168306128928187.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,529 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $242.1818 to $242.210, inclusive. The reporting person undertakes to provide to Danaher Corporation, any securityholder of Danaher Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4. Read SEC document
April 28, 2023 Filed May 1, 2023 21:03 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	0.723	$236.91 Strike: $0.00	$171.29	Disclosure SEC source: 0000313616-23-000154 · wf-form4_168297501220430.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635.378 Underlying: Common Stock · 0.723 shares Expires not disclosed F1 · security: Represents notional dividend accruals on phantom shares in the Danaher stock fund under one or more of the plans that form part of Danaher's deferred compensation program. The number of phantom shares accrued as a result of such notional dividend accruals is based on the closing price of Danaher common stock as reported on the NYSE on the date such dividend accruals are credited to the fund, which is the price shown in Table II, Column 8 above. Effective June 1, 2023, notional dividend accruals on phantom shares in the Danaher stock fund under Danaher's deferred compensation program will no longer be invested in additional notional shares of Danaher common stock and instead will be invested in a notional fixed income investment option. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
February 24, 2023 Filed Feb 28, 2023 22:03 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock option (right to buy) · Derivative	10,849	$0.00 Strike: $249.12	$0.00	Disclosure SEC source: 0000313616-23-000118 · wf-form4_167762177631136.xml · derivative · entry 4 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,849 Underlying: Common Stock · 10,849 shares Expires 2033-02-24 F3 · derivative.exercise_date: One fourth of the options granted become exercisable on each of the first four anniversaries of the grant date, which is February 24, 2023. Read SEC document
February 24, 2023 Filed Feb 28, 2023 22:03 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock options (right to buy) · Derivative	16,274	$0.00 Strike: $249.12	$0.00	Disclosure SEC source: 0000313616-23-000118 · wf-form4_167762177631136.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,274 Underlying: Common Stock · 16,274 shares Expires 2033-02-24 F2 · derivative.exercise_date: One half of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is February 24, 2023. Read SEC document
February 24, 2023 Filed Feb 28, 2023 22:03 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	4,015	$0.00	$0.00	Disclosure SEC source: 0000313616-23-000118 · wf-form4_167762177631136.xml · nonDerivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,029 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One fourth of the RSUs vest on each of the first four anniversaries of the grant date, which is February 24, 2023. Read SEC document
February 24, 2023 Filed Feb 28, 2023 22:03 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	481	$249.12	$119,826.72	Disclosure SEC source: 0000313616-23-000118 · wf-form4_167762177631136.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014 Read SEC document
February 01, 2023 Filed Feb 2, 2023 22:08 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	461	$267.50 Strike: $0.00	$123,317.50	Disclosure SEC source: 0000313616-23-000069 · wf-form4_167537571122801.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 634.655 Underlying: Common Stock · 461 shares Expires not disclosed F1 · security: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F1 · price: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F1 · derivative.underlying_shares: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F1 · balance_after: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one or more of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. Read SEC document
January 27, 2023 Filed Jan 30, 2023 22:04 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	0.163	$265.98 Strike: $0.00	$43.35	Disclosure SEC source: 0000313616-23-000033 · wf-form4_167511622200747.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173.655 Underlying: Common Stock · 0.163 shares Expires not disclosed F1 · security: Represents notional dividend accruals on phantom shares in the Danaher stock fund under one or more of the plans that form part of Danaher's deferred compensation program. The number of phantom shares accrued as a result of such notional dividend accruals is based on the closing price of Danaher common stock as reported on the NYSE on the date such dividend accruals are credited to the fund, which is the price shown in Table II, Column 8 above. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:07 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	11,500	$0.00 Strike: $29.60	$0.00	Disclosure SEC source: 0001209191-23-002180 · doc4.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Ordinary Shares · 11,500 shares Expires 2033-01-03 F3 · derivative.exercise_date: This option shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023. Read SEC document
January 03, 2023 Filed Jan 6, 2023 02:07 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	5,750	$0.00	$0.00	Disclosure SEC source: 0001209191-23-002180 · doc4.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,750 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2023, June 15, 2023, September 15, 2023 and December 15, 2023. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
October 28, 2022 Filed Oct 31, 2022 21:04 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	0.172	$251.80 Strike: $0.00	$43.31	Disclosure SEC source: 0000313616-22-000254 · wf-form4_166725024923517.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173.492 Underlying: Common Stock · 0.172 shares Expires not disclosed F1 · security: Represents notional dividend accruals on phantom shares in the Danaher stock fund under one or more of the plans that form part of Danaher's deferred compensation program. The number of phantom shares accrued as a result of such notional dividend accruals is based on the closing price of Danaher common stock as reported on the NYSE on the date such dividend accruals are credited to the fund, which is the price shown in Table II, Column 8 above. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
July 29, 2022 Filed Aug 2, 2022 21:05 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	0.148	$291.47 Strike: $0.00	$43.14	Disclosure SEC source: 0000313616-22-000202 · wf-form4_165947429925196.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173.32 Underlying: Common Stock · 0.148 shares Expires not disclosed F1 · security: Represents notional dividend accruals on phantom shares in the Danaher stock fund under one or more of the plans that form part of Danaher's deferred compensation program. The number of phantom shares accrued as a result of such notional dividend accruals is based on the closing price of Danaher common stock as reported on the NYSE on the date such dividend accruals are credited to the fund, which is the price shown in Table II, Column 8 above. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
April 29, 2022 Filed Feb 2, 2023 22:13 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	0.172	$251.13 Strike: $0.00	$43.19	Disclosure SEC source: 0000313616-23-000079 · wf-form5_167537596516428.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173.492 Underlying: Common Stock · 0.172 shares Expires not disclosed F1 · security: Represents notional dividend accruals on phantom shares in the Danaher stock fund under one or more of the plans that form part of Danaher's deferred compensation program. The number of phantom shares accrued as a result of such notional dividend accruals is based on the closing price of Danaher common stock as reported on the NYSE on the date such dividend accruals are credited to the fund, which is the price shown in Table II, Column 8 above. Beginning in the third quarter of 2022, the Danaher reporting persons began reporting these quarterly notional dividend accruals on a current basis, which is why this Form 5 only reports the accrual that occurred in the second quarter of 2022. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. Read SEC document
April 01, 2022 Filed Apr 5, 2022 17:41 UTC	Evelo Biosciences, Inc. EVLO · Entity 108468	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $3.36	$0.00	Disclosure SEC source: 0001694665-22-000063 · wf-form4_164919488578075.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-04-01 F1 · derivative.exercise_date: The option vests in 36 substantially equal monthly installments following the grant date and has a term of 10 years. Read SEC document
February 24, 2022 Filed Feb 28, 2022 22:09 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee stock option (right to buy) · Derivative	12,626	$0.00 Strike: $271.56	$0.00	Disclosure SEC source: 0000313616-22-000095 · wf-form4_164608612520257.xml · derivative · entry 3 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,626 Underlying: Common Stock · 12,626 shares Expires 2032-02-24 F2 · derivative.exercise_date: One half of the options granted become exercisable on each of the third and fourth anniversaries of the grant date, which is February 24, 2022. Read SEC document
February 24, 2022 Filed Feb 28, 2022 22:09 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	2,210	$0.00	$0.00	Disclosure SEC source: 0000313616-22-000095 · wf-form4_164608612520257.xml · nonDerivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,495 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One third of the RSUs vest on each of the first, second, and third anniversaries of the grant date, which is February 24, 2022. Read SEC document
February 24, 2022 Filed Feb 28, 2022 22:09 UTC	DANAHER CORP /DE/ DHR · Entity 2871	Tax withholdingCommon Stock	260	$271.56	$70,605.60	Disclosure SEC source: 0000313616-22-000095 · wf-form4_164608612520257.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,285 Read SEC document
February 01, 2022 Filed Feb 2, 2022 22:02 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantDanaher Deferred Compensation Programs - Danaher Stock Fund · Derivative	173	$285.79 Strike: $0.00	$49,441.67	Disclosure SEC source: 0000313616-22-000051 · wf-form4_164383932950126.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173 Underlying: Common Stock · 173 shares Expires not disclosed F1 · security: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F2 · derivative.exercise_price: The notional shares convert on a one-for-one basis. F1 · price: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F3 · derivative.exercise_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F3 · derivative.expiration_date: The vesting terms and manner and form of distribution of amounts contributed or deferred under the program are based upon the provisions of the respective plan, which provisions are summarized in the latest Danaher Corporation annual meeting proxy statement on Schedule 14A as filed with the Securities and Exchange Commission. F1 · derivative.underlying_shares: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. F1 · balance_after: Represents the Company's annual contribution to the Danaher stock fund in the reporting person's account under one of the plans that form part of Danaher's deferred compensation program. The Company contributions are deemed to be invested in a number of unfunded, notional shares of Danaher common stock. The price shown in Table II, Column 8 is the closing price per share of Danaher common stock as reported on the NYSE on the date used to determine the number of notional shares to be credited to the participant's account. Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:18 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $60.87	$0.00	Disclosure SEC source: 0001209191-22-001808 · doc4.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2032-01-03 F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
January 03, 2022 Filed Jan 5, 2022 22:18 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantOrdinary Shares	5,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-001808 · doc4.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs are fully vested. F2 · price: Each RSU represents a contingent right to receive one ordinary share. Read SEC document
March 17, 2021 Filed Mar 19, 2021 20:56 UTC	BICYCLE THERAPEUTICS PLC BCYC · Entity 5993	GrantStock Option (right to buy) · Derivative	32,000	$0.00 Strike: $27.90	$0.00	Disclosure SEC source: 0001209191-21-022111 · doc4.xml · derivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Ordinary Shares · 32,000 shares Expires 2031-03-17 F1 · derivative.exercise_date: The shares underlying this option shall vest in 36 equal monthly installments at the end of each calendar month following the date of grant. Read SEC document
February 24, 2021 Filed Feb 26, 2021 23:49 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantEmployee Stock Option (Right to Buy) · Derivative	13,190	$223.00 Strike: $223.00	$2,941,370.00	Disclosure SEC source: 0000313616-21-000046 · edgar.xml · derivative · entry 2 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,190 Underlying: Common Stock · 13,190 shares Expires 2031-02-24 F2 · derivative.exercise_date: One third of the options granted become exercisable on each of the third, fourth and fifth anniversaries of the grant date, which is February 24, 2021. Read SEC document
February 24, 2021 Filed Feb 26, 2021 23:49 UTC	DANAHER CORP /DE/ DHR · Entity 2871	GrantCommon Stock	2,545	$223.00	$567,535.00	Disclosure SEC source: 0000313616-21-000046 · edgar.xml · nonDerivative · entry 1 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · SVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545 F1 · shares: On the date indicated, Danaher Corporation granted the reporting person restricted stock units (RSUs) in the amount indicated. Since the RSUs are payable solely in common stock, they are being reported in Table I of this Form 4. One third of the RSUs granted vest on each of the third, fourth and fifth anniversaries of the grant date, which is February 24, 2021. Read SEC document
October 01, 2020 Filed Oct 1, 2020 21:17 UTC	MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	Not disclosed Strike: $38.09	Not disclosed	Disclosure SEC source: 0001179110-20-010063 · edgar.xml · derivative · entry 5 Gutierrez-Ramos Jose-Carlos · CIK 0001667657 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-06-23 F1 · price: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. F1 · derivative.exercise_date: Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with that certain Agreement and Plan of Merger, dated as of August 19, 2020, by and among Johnson & Johnson, Vigor Sub, Inc. and the Issuer, pursuant to which, effective immediately prior to the effective time of the merger contemplated thereby (the "Effective Time"), each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which $52.50 exceeds the per share exercise price of such Issuer Option. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.